SEGMENTS

12 Months Ended

Dec. 31, 2023

SEGMENTS [Abstract]

SEGMENTS

13. SEGMENTS

The Company is dedicated to manufacturing, marketing and developing specialty plasma-derived biologics. The Company’s ADMA BioManufacturing segment reflects the Company’s immune globulin manufacturing and development operations in Florida, acquired on June 6, 2017. The Plasma Collection Centers segment consists of ten plasma collection facilities as of December 31, 2023, all of which were operational,collecting plasma, and hold an approved license with the FDA (and of which three facilities have received approvals from the Korean Ministry of Food and Drug Safety as well as FDA approval to implement a Hepatitis B immunization program). The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:

Year Ended December 31, 2023
(in thousands)	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	249,738		$	8,334		$	143		$	258,215
Cost of product revenue		161,157			8,116			-			169,273
Income (loss) from operations		47,525			(4,048	)		(21,845	)		21,632
Interest and other expense, net		(258	)		(1	)		(23,438	)		(23,697	)
Loss on extinguishment of debt		-			-			(26,174	)		(26,174	)
Net income (loss)		47,267			(4,049	)		(71,457	)		(28,239	)
Capital expenditures		2,952			1,819			-			4,771
Depreciation and amortization expense		5,156			3,176			-			8,332
Total assets		246,719			34,733			47,730			329,182

Year Ended December 31, 2022
(in thousands)	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	144,070		$	9,867		$	143		$	154,080
Cost of product revenue		108,882			9,933			-			118,815
Income (loss) from operations		879			(17,908	)		(22,336	)		(39,365	)
Interest and other expense, net		(505	)		(3	)		(19,361	)		(19,869	)
Loss on extinguishment of debt		-			-			(6,670	)		(6,670	)
Net income (loss)		374			(17,911	)		(48,367	)		(65,904	)
Capital expenditures		5,247			8,664			-			13,911
Depreciation and amortization expense		4,709			2,404			-			7,113
Total assets		238,159			37,071			73,231			348,461

Year Ended December 31, 2021
(in thousands)	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	74,936		$	5,864		$	143		$	80,943
Cost of product revenue		74,126			5,644			-			79,770
Loss from operations		(29,294	)		(12,056	)		(17,024	)		(58,374	)
Interest and other expense, net		(218	)		(6	)		(13,050	)		(13,274	)
Net loss		(29,512	)		(12,062	)		(30,074	)		(71,648	)
Capital expenditures		4,877			8,634			-			13,511
Depreciation and amortization expense		4,218			1,273			5			5,496
Total assets		208,391			24,682			43,180			276,253